Drug recall · December 20, 2023
Votrient recall
Why: Failed Dissolution Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66
- Lots / codes
Lot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025
- Quantity
- 2016
- Company
- Siegfried Barbera, SL, Barbera Del Valles, N/A
- Distribution
- Nationwide
- Initiated
- November 20, 2023 · Voluntary: Firm initiated
- Classified
- December 13, 2023
- Reported
- December 20, 2023
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Pazopanib
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.